Cartesian Therapeutics, Inc.
RNAC
주식 순위
#18421
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
주가
$6.27
마지막 동기화: 2026-10-16
시가총액
$189.70M
변동 (1일)
-4.71%
변동 (1년)
839.61%
국가
US
거래 Cartesian Therapeutics, Inc. (RNAC)
카테고리
Healthcare
의 시가총액 Cartesian Therapeutics, Inc.(RNAC)
시가총액: $189.70M
October 2026 기준으로 Cartesian Therapeutics, Inc.의 시가총액은 $189.70M입니다. 이는 당사 데이터에 따르면 Cartesian Therapeutics, Inc.이 세계에서 18421st번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2016부터 2026까지 Cartesian Therapeutics, Inc.의 시가총액 기록
